{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:06Z","timestamp":1791352206227,"version":"4.3.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare overall survival (OS) in patients with relapsed neuroblastoma treated with dinutuximab beta (DB) after relapse with that of two comparator populations: historical controls with no prior anti-disialoganglioside-2 exposure and patients who relapsed after first-line DB maintenance immunotherapy. The objectives were to evaluate the effectiveness of DB in the relapsed setting and to assess a potential legacy effect of prior first-line therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This unanchored indirect comparison used individual patient data from three cohorts: historical controls with no prior anti-GD2 therapy (N\/N), patients who relapsed after first-line DB maintenance immunotherapy and did not receive subsequent DB (DB\/N), and patients treated with DB after relapse without prior exposure (N\/DB). Harmonized eligibility criteria were applied across cohorts, and follow-up was aligned using a common post-relapse index date. Adjusted comparisons were performed using propensity score reweighting. Overall survival was measured from the observed (N\/DB) or imputed (N\/N and DB\/N) post-relapse index date and analyzed using weighted Kaplan\u2013Meier methods and weighted Cox proportional hazards models, with hazard ratios (HR) reported. For the N\/N and DB\/N cohorts, the post-relapse index date was imputed using a quantile regression model estimating the interval from first relapse to initiation of DB, fitted to data from the N\/DB cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 329 patients were assessed, of whom 266 were included in the weighted analyses. Baseline imbalances in age at relapse, time from diagnosis, MYCN status, and International Neuroblastoma Staging System (INSS) stage were largely resolved after weighting. No evidence of a legacy effect of first-line DB exposure was observed, as OS did not differ significantly between patients who relapsed after first-line DB maintenance immunotherapy and historical controls (HR\u00a0=\u00a01.26, 95% CI 0.70\u20132.26; p=0.437). In contrast, DB administered after relapse was associated with significantly improved OS compared with both historical controls (HR\u00a0=\u00a00.53, 95% CI 0.35\u20130.81; p=0.003) and patients who relapsed after first-line DB maintenance immunotherapy (HR\u00a0=\u00a00.42, 95% CI 0.25\u20130.72; p=0.001). These findings were consistent across sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and limitations<\/jats:title>\n                    <jats:p>This adjusted indirect comparison demonstrated that DB administered after relapse was associated with significantly improved OS compared with both historical controls and patients who relapsed after prior first-line DB maintenance immunotherapy. No evidence of a legacy effect of first-line DB immunotherapy was identified. These findings support the clinical relevance of DB in the relapsed setting and indicate that prior first-line DB maintenance alone was not associated with a persistent post-relapse survival advantage. The study did not evaluate DB retreatment after prior first-line exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1933438","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:25Z","timestamp":1791348805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Overall survival after relapse in high-risk neuroblastoma: an adjusted indirect comparison of post-relapse dinutuximab beta, historical controls, and relapse after first-line dinutuximab beta maintenance"],"prefix":"10.3389","volume":"16","author":[{"given":"Holger N.","family":"Lode","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Medicine Greifswald","place":["Greifswald, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Holko","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Wieczorek","sequence":"additional","affiliation":[{"name":"Paediatric Haematology Oncology, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"\u015aladowska","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College","place":["Krakow, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Siebert","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Medicine Greifswald","place":["Greifswald, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Valteau-Couanet","sequence":"additional","affiliation":[{"name":"Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garaventa","sequence":"additional","affiliation":[{"name":"Oncology Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) Istituto Giannina Gaslini","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Ca\u00f1ete","sequence":"additional","affiliation":[{"name":"Hospital Universitario y Politecnico La Fe","place":["Valencia, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Anderson","sequence":"additional","affiliation":[{"name":"University College London (UCL) Great Ormond Street Institute of Child Health","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Yaniv","sequence":"additional","affiliation":[{"name":"Schneider Children\u2019s Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University","place":["Petach Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifra","family":"Ash","sequence":"additional","affiliation":[{"name":"Schneider Children's Medical Center of Israel","place":["Petach Tikva, Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Moreno","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology & Oncology, Vall d\u2019Hebron Barcelona Hospital","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliet","family":"Gray","sequence":"additional","affiliation":[{"name":"Centre for Cancer Immunology, University of Southampton","place":["Southampton, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Luksch","sequence":"additional","affiliation":[{"name":"Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Laureys","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology\/Oncology and Stem Cell Transplantation University Hospital Ghent","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cormac","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology, Children's Health Ireland","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Manzitti","sequence":"additional","affiliation":[{"name":"Oncology Unit, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) Istituto Giannina Gaslini","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Troschke-Meurer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, University Medicine Greifswald","place":["Greifswald, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Kawalec","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Drug Research, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College","place":["Krakow, Poland"]},{"name":"Centrum HTA Sp. z o.o.","place":["Krak\u00f3w, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth L.","family":"Ladenstein","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Saint Anna Children\u2019s Hospital, Medical University","place":["Vienna, Austria"]},{"name":"Department of Pediatrics, Medical University Vienna","place":["Vienna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/children8060482","article-title":"Novel treatments and technologies applied to the cure of neuroblastoma","volume":"8","author":"Paraboschi","year":"2021","journal-title":"Children (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2026.116254","article-title":"Current treatment strategies for first relapse of high-risk neuroblastoma","volume":"236","author":"Castelli","year":"2026","journal-title":"Eur J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02478","article-title":"Outcomes following GD2-directed postconsolidation therapy for neuroblastoma after cessation of random assignment on ANBL0032: A report from the Children\u2019s Oncology Group","volume":"40","author":"Desai","year":"2022","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1082771","article-title":"Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma","volume":"13","author":"Wieczorek","year":"2023","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14030934","article-title":"Assessment of chemo-immunotherapy regimens in patients with refractory or relapsed neuroblastoma: A systematic review with meta-analysis of critical oncological outcomes","volume":"14","author":"Olgun","year":"2025","journal-title":"J Clin Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114001","article-title":"Chemo-immunotherapy with dinutuximab beta in patients with relapsed\/progressive high-risk neuroblastoma: does chemotherapy backbone matter","volume":"202","author":"Raiser","year":"2024","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01868","article-title":"Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial","volume":"44","author":"Gray","year":"2026","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1186\/s12885-022-09776-x","article-title":"Isolated central nervous system relapses in patients with high-risk neuroblastoma: clinical presentation and prognosis: experience of the Polish Paediatric Solid Tumours Study Group","volume":"22","author":"Wieczorek","year":"2022","journal-title":"BMC Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01155-3","article-title":"Efficacy and safety of anti-GD2 immunotherapy with dinutuximab beta in the treatment of relapsed\/refractory high-risk neuroblastoma","volume":"20","author":"Wieczorek","year":"2025","journal-title":"Target Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1736165","article-title":"Dinutuximab beta versus historical controls in the treatment of relapsed neuroblastoma: unadjusted and adjusted indirect comparisons","volume":"15","author":"Lode","year":"2026","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.06.010","article-title":"Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry","volume":"45","author":"Garaventa","year":"2009","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2021","journal-title":"Clin Kidney J"},{"key":"B17","unstructured":"Epar 2017\n          \n          \n          \n          2017"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02457-x","article-title":"Long-term, continuous infusion of single-agent dinutuximab beta for relapsed\/refractory neuroblastoma: an open-label, single-arm, Phase 2 study","volume":"129","author":"Lode","year":"2023","journal-title":"Br J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165252","article-title":"Dinutuximab beta maintenance therapy in patients with high-risk neuroblastoma in first-line and refractory\/relapsed settings\u2014real-world data","volume":"12","author":"Wieczorek","year":"2023","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01630","article-title":"Anti-GD2 antibody dinutuximab beta and low-dose interleukin 2 after haploidentical stem-cell transplantation in patients with relapsed neuroblastoma: a multicenter, phase I\/II trial","volume":"41","author":"Flaadt","year":"2023","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/19420862.2017.1402997","article-title":"Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18\/CHO","volume":"10","author":"Mueller","year":"2018","journal-title":"MAbs"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.25215","article-title":"Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study","volume":"5","author":"Ladenstein","year":"2013","journal-title":"MAbs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-025-03853-w","article-title":"Management and outcome of children with high-risk neuroblastoma: insights from the Spanish Society of Pediatric Hematology and Oncology (SEHOP) neuroblastoma group on refractory and relapse\/progressive disease","volume":"27","author":"Mart\u00ednez de las Heras","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: A report from the Children\u2019s Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1356","article-title":"Immunotherapy of neuroblastoma: Facts and hopes","volume":"28","author":"Anderson","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004399","article-title":"Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00405-x","article-title":"Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1","volume":"3","author":"Mabe","year":"2022","journal-title":"Nat Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03874-6","article-title":"GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1\/2 trial","volume":"31","author":"Locatelli","year":"2025","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:53:26Z","timestamp":1791348806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1933438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":28,"alternative-id":["10.3389\/fonc.2026.1933438"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1933438","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1933438"}}